EX-10.18



 Exhibit 10.18 

CONFIDENTIAL TREATMENT REQUESTED 

EIGHTH AMENDMENT 
 TO

 LICENSE AGREEMENT 

THIS EIGHTH AMENDMENT TO LICENSE AGREEMENT (this “Eighth Amendment”), effective June 29, 2012, is by and among:

 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice” and, together with Angiotech US, the “Licensor”); and 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”). 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp. (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3
(the “Original License Agreement”); 
 WHEREAS, effective as of November 4, 2005, all of the assets of
Biomaterials were sold to Angiotech US and Biomaterials was wound up and in connection with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials
under the Original License Agreement as if it were the original party thereto; 
 WHEREAS, the Licensor and Histogenics entered into
that certain Amendment to License Agreement, dated as of August 31, 2007, that certain Second Amendment to License Agreement, dated as of January 1, 2008, that certain Third Amendment to License Agreement, dated as of April 15, 2008,
that certain Fourth Amendment to. License Agreement, dated as of November 1, 2008, that certain Fifth Amendment to License Agreement, dated as of August 6, 2010, that certain Reinstatement Agreement and Sixth Amendment to License
Agreement, dated as of February 8, 2011, and that certain Seventh Amendment, effective as of March 31, 2011 (the Original License Agreement, as amended by the foregoing amendments, shall be referred to herein as the
“Agreement”); 
 WHEREAS, Section 4.1 of the Original License Agreement contained a diligence obligation
requiring Histogenics to **** 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****; 

WHEREAS, Histogenics desires to amend the Agreement to remove the provision requiring ****; 

WHEREAS, Angiotech US, Angiodevice, and Histogenics have determined that it is in their best interests to amend the provisions
regarding diligence obligations in Section 4.1 of the Agreement; 
 NOW, THEREFORE, in consideration of the mutual
promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows: 

 

	1.	Amendment. 

 1.1 Section 4.1 of the Agreement is hereby amended and restated in its
entirety to state as follows: 
 “4.1 Diligence Obligations. It is understood and acknowledged that part of the consideration for
this License is Histogenics’s intention to bring one or more Eligible Products to market through a program for exploitation of the Licensed Technology and, once commercialized, thereafter to continue active, diligent marketing and sales efforts
for Eligible Products throughout the life of this Agreement. 
  

	2.	Miscellaneous 

 2.1 Entire Agreement; Confirmation of Agreement. Except as
specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect. 
 2.2 Counterparts. This
Eighth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as
original signatures. In making proof of this Eighth Amendment, it shall not be necessary to produce or account for more than one such counterpart. 

[Signature Page Follows] 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Eighth Amendment to be executed and
delivered by the respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	/s/ Tammy Neske	 		 	By:	 	/s/ K. Thomas Bailey
		 	Name:	 	 Tammy Neske
	 		 		 	Name:	 	K. Thomas Bailey
		 	Title:	 	Authorized Signatory	 		 		 	Title:	 	Director
		 	Date:	 	June 29, 2012	 		 		 	Date:	 	June 29, 2012
					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	 /s/ Patrick O’Donnell
	 		 		 		 	
		 	Name:	 	Patrick O’Donnell	 		 		 		 	
		 	Title:	 	President & CEO	 		 		 		 	
		 	Date:	 	June 29, 2012	 		 		 		 	


  
 - 3 -